Search research articles
Contact Us
Filters
Showing results (91-100 of 153) with videos related to
Page
of 16
Sort By:
Plos One
|
July 26, 2012
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer
Alexandre Ho-Pun-Cheung, Hervé Bazin, Nadège Gaborit, et al.
Journal of Hepatology
|
May 16, 2009
Identification of proteomic changes during human liver development by 2D-DIGE and mass spectrometry
Jean Paul Brizard, Jeanne Ramos, Agnés Robert, et al.
Cancers
|
March 29, 2020
A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score
Charlotte Maulat, Cindy Canivet, Célia Touraine, et al.
Journal of Hepatology
|
April 24, 2012
Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication
Stéphanie Faure, Astrid Herrero, Boris Jung, et al.
Liver Cancer
|
June 12, 2018
Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study
Masatoshi Kudo, Yoon-Koo Kang, Joong-Won Park, et al.
British Journal of Cancer
|
April 5, 2019
Sorafenib alone vs. sorafenib plus GEMOX as 1<sup>st</sup>-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
Eric Assenat, Georges-Philippe Pageaux, Simon Thézenas, et al.
Pathogens (Basel, Switzerland)
|
January 21, 2022
GOLT1B Activation in Hepatitis C Virus-Infected Hepatocytes Links ER Trafficking and Viral Replication
Jacqueline Butterworth, Damien Gregoire, Marion Peter, et al.
JAMA Oncology
|
October 5, 2023
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial
Shukui Qin, Masatoshi Kudo, Tim Meyer, et al.
International Journal of Cancer
|
January 6, 2021
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)
Eric Assenat, Laurent Mineur, Caroline Mollevi, et al.
JHEP Reports : Innovation in Hepatology
|
April 15, 2024
A phase Ib/II trial of capmatinib plus spartalizumab <i>vs.</i> spartalizumab alone in patients with pretreated hepatocellular carcinoma
Armando Santoro, Eric Assenat, Thomas Yau, et al.
Page
of 16
Search research articles
Search
Showing results (91-100 of 153) with videos related to
Sort By:
Page
of 16
Plos One
|
July 26, 2012
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer
Alexandre Ho-Pun-Cheung, Hervé Bazin, Nadège Gaborit, et al.
Journal of Hepatology
|
May 16, 2009
Identification of proteomic changes during human liver development by 2D-DIGE and mass spectrometry
Jean Paul Brizard, Jeanne Ramos, Agnés Robert, et al.
Cancers
|
March 29, 2020
A New Score to Predict the Resectability of Pancreatic Adenocarcinoma: The BACAP Score
Charlotte Maulat, Cindy Canivet, Célia Touraine, et al.
Journal of Hepatology
|
April 24, 2012
Excessive alcohol consumption after liver transplantation impacts on long-term survival, whatever the primary indication
Stéphanie Faure, Astrid Herrero, Boris Jung, et al.
Liver Cancer
|
June 12, 2018
Regional Differences in Efficacy, Safety, and Biomarkers for Second-Line Axitinib in Patients with Advanced Hepatocellular Carcinoma: From a Randomized Phase II Study
Masatoshi Kudo, Yoon-Koo Kang, Joong-Won Park, et al.
British Journal of Cancer
|
April 5, 2019
Sorafenib alone vs. sorafenib plus GEMOX as 1<sup>st</sup>-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial
Eric Assenat, Georges-Philippe Pageaux, Simon Thézenas, et al.
Pathogens (Basel, Switzerland)
|
January 21, 2022
GOLT1B Activation in Hepatitis C Virus-Infected Hepatocytes Links ER Trafficking and Viral Replication
Jacqueline Butterworth, Damien Gregoire, Marion Peter, et al.
JAMA Oncology
|
October 5, 2023
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial
Shukui Qin, Masatoshi Kudo, Tim Meyer, et al.
International Journal of Cancer
|
January 6, 2021
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1)
Eric Assenat, Laurent Mineur, Caroline Mollevi, et al.
JHEP Reports : Innovation in Hepatology
|
April 15, 2024
A phase Ib/II trial of capmatinib plus spartalizumab <i>vs.</i> spartalizumab alone in patients with pretreated hepatocellular carcinoma
Armando Santoro, Eric Assenat, Thomas Yau, et al.
Page
of 16